Malignant pleural mesothelioma (MPM) is an uncommon
|
|
- Barbara Atkinson
- 6 years ago
- Views:
Transcription
1 Risk Factors for Major Complications After Extrapleural Pneumonectomy for Malignant Pleural Mesothelioma Marc de Perrot, MD, Karen McRae, MD, Masaki Anraku, MD, Keyvan Karkouti, MD, Thomas K. Waddell, MD, Andrew F. Pierre, MD, Gail Darling, MD, Shaf Keshavjee, MD, and Michael R. Johnston, MD Division of Thoracic Surgery and Department of Anesthesia, Toronto General Hospital, University Health Network, Toronto, Ontario, Canada Background. Factors associated with increased risk of major complications were older (60 8 years versus 56 major complications after extrapleural pneumonectomy 12 years, respectively; p 0.2) and received more RBC (EPP) for malignant pleural mesothelioma are not well transfusions ( units versus units, characterized; in particular, the risks of induction chemotherapy and red blood cell (RBC) transfusion have notmore frequently after right-sided EPP than after left- respectively; p 0.02). Major complications occurred been well defined. sided EPP (54% versus 21%, p 0.007). Induction chemotherapy had no impact on the risk of major complications Methods. We reviewed our experience with 62 consecutive EPP (28 right sided) performed in our institution(p 0.5). Transfusion of more than 4 units of RBC p ( for malignant pleural mesothelioma between January 0.01) and right-sided EPP p ( 0.01) were associated with 1993 and May A total of 44 patients underwentincreased risk of major complications after EPP in multivariate analysis. induction chemotherapy with cisplatin-based therapy. Results. The majority of patients (88%) received RBC Conclusions. Right EPP and more than 4 units of RBC transfusions (median, 4 units; range, 0 to 18 units). transfusion are associated with increased risk of major Patients undergoing induction chemotherapy had lower complications. Although patients undergoing induction preoperative hemoglobin ( g/l versus chemotherapy received more RBC transfusions, induction chemotherapy did not directly impact the risk of g/l in the remaining patients, p 0.02) and received more RBC transfusions ( units versus major complications. units in the remaining patients, p 0.007). Twenty-two patients (35%) experienced major postoperative complications and 4 of them died (6.5%). Patients experiencing 2008 by The Society of Thoracic (Ann Thorac Surg 2008;85: ) Surgeons Malignant pleural mesothelioma (MPM) is an uncommon neoplasm associated with a median survival of approximately 10 months from the time of histologic diagnosis [1]. Extrapleural pneumonectomy (EPP) has been performed in selected patients with MPM, but its role has remained limited because of the morbidity and mortality associated with the procedure. Recent series have demonstrated a dramatic reduction in the operative mortality since the 1970s, with a 30-day mortality ranging between 3% and 8% [2 4]. However, despite the improvement in operative mortality, the rate of major postoperative complications remains high. In addition, induction chemotherapy has been increasingly used before EPP with the hope of improving long-term survival, but its administration before surgery may increase the risk of postoperative complications [5 7]. We, therefore, performed a retrospective analysis of patients Accepted for publication Nov 26, Address correspondence to Dr de Perrot, Division of Thoracic Surgery, Toronto General Hospital, 9N-961, 200 Elizabeth St, Toronto, Ontario, M5G 2C4, Canada; marc.deperrot@uhn.on.ca. undergoing EPP for MPM in our institution to identify factors associated with an increased risk of postoperative complications. Material and Methods A total of 62 consecutive patients with biopsy-proven MPM underwent EPP in our institution between January 1993 and May Most patients (70%, n 45) underwent surgery between January 2001 and May A retrospective chart review was performed after approval by the Institutional Review Board. The Institutional Review Board approval waived the need for patient consent to perform the study. All patients were evaluated preoperatively by chest radiograph, contrast-enhanced computed tomography (CT) scan of the chest and abdomen, spirometry and ventilation-perfusion scan. Magnetic resonance imaging (MRI) was used in selected cases. Brain CT or MRI as well as bone scan were performed if clinically indicated. Resectability was defined by tumor confined to one 2008 by The Society of Thoracic Surgeons /08/$34.00 Published by Elsevier Inc doi: /j.athoracsur
2 Ann Thorac Surg DE PERROT ET AL 2008;85: RISK FACTORS FOR COMPLICATIONS AFTER EPP hemithorax with no evidence of mediastinal organ, spine, diffuse chest wall involvement, or transdiaphragmatic extension. Positron emission tomography scan was not available in our institution until recently and was not performed for any of these patients. Mediastinoscopy was always performed if the mediastinal lymph nodes were larger than or equal to 1.5 cm in their greatest diameter on the chest CT. If lymph nodes were smaller than 1.5 cm in their largest diameter, mediastinoscopy was performed on a case-by-case basis, mainly according to the surgeon s preference. Extrapleural pneumonectomy included en bloc resection of the lung, parietal pleura, ipsilateral diaphragm, and ipsilateral pericardium. Previous biopsy sites were removed with a limited chest wall resection. Systematic mediastinal lymph node dissection or sampling was performed in all patients to allow accurate surgical staging of the disease. Paraesophageal, peridiaphragmatic, and subcarinal nodal stations were examined for tumors located on the right and on the left side. Additionally, paratracheal nodes were examined for right-sided tumors, and aortopulmonary window and para-aortic nodes were sampled for left-sided tumors. Tumors were staged according to the staging system developed by the International Mesothelioma Interest Group and published by the American Joint Committee on Cancer (AJCC) and the International Union Against Cancer (UICC) [8]. Postoperative deaths included all patients who died within 30 days of surgery or during the same hospitalization. Postoperative complications were defined as complications within 30 days of surgery or during the same hospital stay. Major complications were defined by complications of grade 3 or higher according to the Table 1. Patient Characteristics (n 62) Age, years 58 (21 75) 60 years old years old 38 Sex Male 51 Female 11 Induction chemotherapy Yes 44 No 18 Operated side Right 28 Left 34 Histology Epithelial 44 Biphasic 13 Sarcomatoid 3 Other 2 Pathologic stage I 2 II 10 III 44 IV 6 Table 2. Postoperative Complications a Complications Number of Patients (%) Major complications 22 (35) Cardiac complications Atrial fibrillation 13 (21) Cardiac arrest 1 (2) Cardiac herniation 1 (2) Pulmonary complications Pulmonary emboli 2 (3) Acute lung injury/pneumonia 2 (3) Bronchopleural fistula 2 (3) Empyema 1 (2) Gastrointestinal complications Abdominal herniation 2 (3) Esophageal perforation 1 (2) Miscellaneous Hemothorax 1 (2) Chylothorax 1 (2) a Some patients had more than one complication. National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) 3.0 guidelines. The number of units of red blood cell (RBC) transfusion was recorded during the hospital stay. Indications for blood transfusions were hemoglobin levels of less than 80 g/l, or hemoglobin levels between 80 and 100 g/l and a history of ischemic heart disease or clinical intolerance to anemia with tachycardia and systemic hypotension. Estimated blood loss was recorded intraoperatively. Results are presented in absolute number and percentage, median and range, or mean SD. For statistical analysis, major complications were grouped as a composite endpoint because of the low incidence of each individual complication. Variables tested for their potential impact on major postoperative complications and survival were induction chemotherapy (yes versus no), age greater than 60 years old (yes versus no), sex (male versus female), transfusions of more than 4 units of red blood cells (yes versus no), stage (I and II versus III and IV), and side of surgery (right versus left). Categorical variables were compared by 2 analysis and numerical variables by Student t test. Overall survival was estimated using the method of Kaplan-Meier. Differences in survival were tested for significance by the log-rank test. Multivariate analysis was assessed by logistic regression analysis for categorical variables and by the Cox proportional hazards stepwise model for numerical variables. Statview V (Abacus Concepts, Berkeley, California) was used for all analyses. A p value less than 0.05 was considered significant. Results 1207 Most patients were males and presented with epithelial cell type (Table 1). A total of 22 patients (35%) presented with major postoperative complications and 4 (6.5%) died postoperatively (Table 2). The causes of death were GENERAL THORACIC
3 1208 DE PERROT ET AL Ann Thorac Surg RISK FACTORS FOR COMPLICATIONS AFTER EPP 2008;85: Table 3. Risk Factors for Major Complications Risk Factors Univariate Analysis p Value Multivariate Analysis p Value 95% CI Male sex Age 60 years Right-sided tumor Transfusion 4 units RBC Induction chemotherapy Disease stage I and II CI confidence interval; RBC red blood cells. Fig 1. The rate of major complications was 54% after right extrapleural pneumonectomy (EPP) and 21% after left EPP (p 0.007). bronchopleural fistula with empyema (n 1), cardiac arrhythmia (n 1), cardiac herniation (n 1), and aspiration pneumonia (n 1). All deaths occurred after right EPP. The operative mortality was therefore 14% (4 of 28) after right EPP and 0% after left EPP (p 0.02). Eight patients required reoperation for hemothorax (n 1), chylothorax (n 1), cardiac herniation due to dehiscence of the pericardial patch (n 1), abdominal herniation due to dehiscence of the diaphragmatic patch (n 2), esophageal perforation (n 1), and empyema requiring a Clagett window (n 1). One patient presenting with a small bronchopleural fistula (about 5 mm) and no empyema at 4 weeks postoperatively underwent immediate closure of the fistula with a pectoralis major muscle flap with no further complication. Six patients required reintubation or prolonged mechanical ventilation and 2 required a temporary tracheostomy during their hospital stay. The rate of major complications was significantly higher after right EPP than after left EPP (Fig 1). Patients experiencing major complications were also older (60 8 years versus years, respectively; p 0.2) than patients who experienced minor or no complications. A total of 44 patients received two or three cycles of cisplatin-based doublet induction chemotherapy. Cisplatin was combined with vinorelbine (n 20), pemetrexed (n 18), adriamycin (n 3), or gemcitabine (n 3). Two patients had pulmonary emboli during chemotherapy and required inferior vena cava filter insertion before their EPP. No recurrent pulmonary emboli were observed at the time of surgery and thereafter in these 2 patients. The mean preoperative hemoglobin was g/l, but was significantly lower in patients who underwent induction chemotherapy when compared with patients who did not ( g/l versus g/l, respectively; p 0.02). The majority of patients (88%) received RBC transfusions (median, 4 units; range, 0 to 18 units; Fig 2). Estimated intraoperative blood loss ranged between 900 and 6,500 ml with a median of 2,000 ml. Patients undergoing induction chemotherapy received more RBC transfusions than patients who did not have induction therapy ( units versus units, respectively; p 0.02). Patients experiencing major complications also received more RBC transfusions ( units versus units, respectively; p 0.02) than patients who experienced minor or no complications. Factors associated with increased risk of major postoperative complications after multivariate analysis were right-sided EPP and more than 4 units of RBC transfusion (Table 3). Patient s age, sex, stage of disease, and induction chemotherapy was not associated with an increased risk of major postoperative complication. The overall 3- and 5-year survival was 27% and 23%, respectively. There was no significant difference in sur- Fig 2. Red blood cell transfusions in patients undergoing extrapleural pneumonectomy. Fig 3. Impact of red blood cell (RBC) transfusions on long-term survival. (Solid line 4 units RBC transfusion; broken line 4 units RBC transfusion.)
4 Ann Thorac Surg DE PERROT ET AL 2008;85: RISK FACTORS FOR COMPLICATIONS AFTER EPP Table 4. Impact of Red Blood Cell (RBC) Transfusion on Survival in Cox Proportional Hazards Analysis Variables p Value 95% CI Male sex Age 60 years Right-sided tumor Transfusion 4 units RBC Induction chemotherapy Disease stage I and II CI confidence interval. vival between right and left EPP, with a 3-year survival of 23% and 30%, respectively (p 0.8). However, survival was significantly worse in patients receiving more than 4 units of RBC transfusion (3-year survival of 14% versus 36% in remaining patients, p 0.03; Fig 3). Cox proportional hazards analysis demonstrated that the impact of RBC transfusion on long-term survival remained close to statistical significance after adjusting for other variables such as stage of disease, patient s age and sex, side of surgery, and induction chemotherapy (Table 4). Comment This study confirms that EPP can be performed with a low operative mortality. However, major complications still occur in a large proportion of patients. The overall incidence of major complications was 35%, with an operative mortality of 6.5% in our experience, confirming the results from other series recently published in the literature [2 4]. The rate of major complications and postoperative deaths was significantly higher after right-sided EPP than after left-sided EPP. Major complications developed in more than 50% of patients undergoing right-sided EPP, and all 4 postoperative deaths reported in our series occurred after right-sided EPP. Stewart and coworkers [3] made similar observations in their analysis of risk factors for postoperative morbidity after EPP. They observed that right EPP was associated with an increased risk of pneumonia and higher rate of admission to the intensive care unit [3]. Opitz and colleagues [4] reported a series of 63 patients undergoing EPP after induction chemotherapy and observed an incidence of postpneumonectomy empyema of 16%. We did not observe an increased rate of postpneumonectomy empyema despite induction chemotherapy in our series. In 2 patients (4%), an empyema developed after EPP, one of them being related to bronchopleural fistula. The reason for such a difference in the incidence of postpneumonectomy empyema between both series is unclear. We do perform frequent irrigation of the pleural space with povidone-iodine intraoperatively and maintain the patients on antibiotics until removal of the chest tube. The chest tube is kept for 24 to 72 hours and is usually removed once the drainage from the postpneumonectomy space becomes serous Induction chemotherapy followed by right pneumonectomy for nonsmall-cell lung cancer can have a high mortality, as high as 24% in some series [9, 10]. The mortality seems to be related to an increased risk of acute lung injury. Interestingly, right pneumonectomy for MPM after induction chemotherapy may not carry the same risk of acute lung injury. Although Stewart and associates [3] reported a higher rate of acute lung injury after induction therapy for MPM, in our experience and in that reported by Opitz and colleagues [4], in only 1 patient in each series did acute lung injury develop postoperatively. The lower risk of acute lung injury after EPP for MPM could be related to the decreased function of the diseased lung with progressive shift of the mediastinum to the diseased side and redistribution of blood flow to the contralateral lung during the months before the pneumonectomy. Hence, patients undergoing pneumonectomy for MPM may already be partially pneumonectomized, and the surgery could cause less physiologic stress on the heart and contralateral lung. The rate of RBC transfusions for EPP has not been reported previously. We observed that only about 12% of our patients could undergo EPP without RBC transfusions and that the median number of RBC transfused was 4 units in our series. Patients undergoing induction chemotherapy had significantly lower preoperative hemoglobin and required significantly more units of RBC transfusion at the time of surgery. Transfusion of more than 4 units of RBC was a risk factor for major postoperative complications. Interestingly, a similar observation has been reported for cardiac surgery in our institution [11, 12]. Transfusion of 5 units of RBC or more was associated with an eightfold increase in the odds of death after cardiac surgery despite adjusting for multiple potential confounding variables [11, 12]. Several studies have demonstrated an association between allogeneic RBC transfusion and increased morbidity and mortality after major pulmonary resections [13, 14]. Although it remains questionable whether RBC transfusion has a direct causative impact on postoperative complications, a large volume of RBC transfusion has been demonstrated to cause marked physiologic perturbations that can result in organ dysfunction and transfusion-related acute lung injury. Stewart and coworkers [3] reported that they routinely administer aprotinin for EPP to reduce blood loss. Antifibrinolytic agents such as aprotinin or tranexamic acid should only be useful if there is excessive fibrinolysis at the time of surgery or thereafter. We prospectively assessed the degree of fibrinolysis in the last 6 patients reported in this series. Thromboelastography was performed before surgery, at the end of surgery, and at 24 hours after surgery with the hope to demonstrate the presence of fibrinolysis to support the use of antifibrinolytic therapy for EPP. Thromboelastography has been extensively used to guide therapy for coagulation disorders in cardiac surgery and is one of the most sensitive methods for detecting perioperative fibrinolysis [15, 16]. Interestingly, the thromboelastography coagulation index remained within normal range at the end of the GENERAL THORACIC
5 1210 DE PERROT ET AL Ann Thorac Surg RISK FACTORS FOR COMPLICATIONS AFTER EPP 2008;85: surgery and at 24 hours postoperatively in each of our patients (data not shown). As no significant alteration in fibrinolysis was detected at any time point, we currently do not recommend the routine administration of antifibrinolytic in patients undergoing EPP in our institution. Aprotinin could potentially increase the risk of renal dysfunction, thrombosis, and other complications without providing any advantages to reduce the risk of bleeding [17]. The use of recombinant human erythropoietin to correct preoperatively any chemotherapy-induced anemia may be another strategy to minimize the risk of RBC transfusion at the time of surgery. This option was recently questioned, however, because of the potential increased risk of thrombotic events in patients with malignancy when the hemoglobin is raised above 120 g/l [18, 19]. We therefore would not recommend using it routinely until further studies are performed to determine its efficacy and safety before EPP in patients with MPM. The potential impact of perioperative RBC transfusion on long-term outcome requires further evaluation. Numerous studies have looked at the impact of RBC transfusion on outcome after surgery for stage I nonsmall-cell lung cancer, and the results have remained conflicting. Several authors found that transfusion was a significant independent predictor of earlier recurrence and cancerrelated death, whereas others did not [13, 20]. It remains unclear, however, whether RBC transfusion could be an indirect prognostic marker, whereas the true prognostic marker is anemia, as suggested by recent studies [21, 22]. Allogeneic blood transfusion can also impair the immune system and lead to increased risk of tumor recurrence [23]. This mechanism may be particularly important in MPM, as a strong immune reaction appears to be associated with better outcome [24]. In conclusion, EPP can be performed with a relatively low operative mortality. However, the morbidity remains high. Risk factors for major postoperative complications are right-sided EPP and transfusion of more than 4 units of allogeneic RBC. Induction chemotherapy was associated with an increased rate of RBC transfusion but did not increase the risk of major postoperative complications in our experience. References 1. Robinson BWS, Lake RA. Advances in malignant mesothelioma. N Engl J Med 2005;353: Sugarbaker DJ, Jaklitsch MT, Bueno R, et al. Prevention, early detection, anad management of complications after 328 consecutive extrapleural pneumonectomies. J Thorac Cardiovasc Surg 2004;128: Stewart DJ, Martin-Ucar AE, Edwards JG, West K, Waller DA. Extra-pleural pneumonectomy for malignant pleural mesothelioma: the risk of induction chemotherapy, rightsided procedures and prolonged operations. Eur J Cardiothorac Surg 2005;27: Opitz I, Kestenholz P, Lardinois D, et al. Incidence and management of complications after neoadjuvant chemotherapy followed by extrapleural pneumonectomy for malignant pleural mesothelioma. Eur J Cardiothorac Surg 2006;29: de Perrot M, Uy K, Anraku M, et al. Impact of lymph node metastasis on outcome after extrapleural pneumonectomy for malignant pleural mesothelioma. J Thorac Cardiovasc Surg 2007;133: Flores RM, Krug LM, Rosenzweig KE, et al. Induction chemotherapy, extrapleural pneumonectomy, and postoperative high-dose radiotherapy for locally advanced malignant pleural mesothelioma: a phase II trial. J Thorac Oncol 2006;1: Weder W, Kestenholz P, Taverna C, et al. Neoadjuvant chemotherapy followed by extrapleural pneumonectomy in malignant pleural mesothelioma. J Clin Oncol 2004;22: International Mesothelioma Interest Group. A proposed new international TNM staging system for malignant pleural mesothelioma. Chest 1995;108: Martin J, Ginsberg RJ, Abolhoda A, et al. Morbidity and mortality after neoadjuvant therapy for lung cancer: the risks of right pneumonectomy. Ann Thorac Surg 2001;72: Darling GE, Abdurahman A, Yi QL, et al. Risk of a right pneumonectomy: role of bronchopleural fistula. Ann Thorac Surg 2005;79: Karkouti K, O Farrell R, Yau TM, Beattie WS. Prediction of massive blood transfusion in cardiac surgery. Can J Anesth 2006;53: Karkouti K, Wijeysundera DN, Yau TM, et al. The independent association of massive blood loss with mortality in cardiac surgery. Transfusion 2004;44: Thomas P, Michelet P, Barlesi F, et al. Impact of blood transfusions on outcome after pneumonectomy for thoracic malignancies. Eur Respir J 2007;29: Harpole DH, DeCamp MM, Daley J, Hur K, Oprian CA, Khuri SF. Prognostic models of thirty-day mortality and morbidity after major pulmonary resection. J Thorac Cardiovasc Surg 1999;117: Spiess BD, Tuman KJ, McCarthy RJ, DeLaria GA, Schillo R, Ivanovich AD. Thromboelastography as an indicator of postcardiopulmonary bypass coagulopathies. J Clin Monit 1987; 3: Kurata M, Horii I. Blood coagulation tests in toxicological studies review of methods and their significance for drug safety assessment. J Toxicol Sci 2004;29: Mangano DT, Tudor IC, Dietzel C. The risk associated with aprotinin in cardiac surgery. N Engl J Med 2006;354: Wright JR, Ung YC, Julian JA, et al. Randomized, doubleblind, placebo-controlled trial of erythropoietin in nonsmall-cell lung cancer with disease-related anemia. J Clin Oncol 2007;25: Steinbrook R. Erythropoietin, the FDA, and oncology. N Engl J Med 2007;356: Nosotti M, Rebulla P, Riccardi D, et al. Correlation between perioperative blood transfusion and prognosis of patients subjected to surgery for stage I lung cancer. Chest 2003;124: Yovino S, Kwok Y, Krasna M, Bangalore M, Suntharalingam M. An association between preoperative anemia and decreased survival in early-stage non-small-cell lung cancer patients treated with surgery alone. Int J Radiat Oncol Biol Phys 2005;62: Berardi R, Brunelli A, Tamburrano T, et al. Perioperative anemia and blood transfusions as prognostic factors in patients undergoing resection for non-small cell lung cancers. Lung Cancer 2005;49: Ottonello L, Ghio M, Contini P, et al. Nonleukoreduced red blood cell transfusion induces a sustained inhibition of neutrophil chemotaxis by stimulating in vivo production of transforming growth factor-beta1 by neutrophils: role of the immunoglobulinlike transcript 1, sfasl, and shla-i. Transfusion 2007;47: Anraku M, Cunningham KS, Yun Z, et al. Impact of tumorinfiltrating T cells on survival in patients with malignant pleural mesothelioma. J Thorac Cardiovasc Surg. In press.
Original Article. Keywords: Mesothelioma; surgery; platelet
Original Article Clinical role of a new prognostic score using platelet-tolymphocyte ratio in patients with malignant pleural mesothelioma undergoing extrapleural pneumonectomy Tetsuzo Tagawa 1,2, Masaki
More informationThe surgeon: new surgical aproaches
The surgeon: new surgical aproaches Paul Van Schil, MD Department of Thoracic and Vascular Surgery Antwerp University, Belgium no disclosures, no conflict of interest Malignant pleural mesothelioma: clinical,
More informationThe right middle lobe is the smallest lobe in the lung, and
ORIGINAL ARTICLE The Impact of Superior Mediastinal Lymph Node Metastases on Prognosis in Non-small Cell Lung Cancer Located in the Right Middle Lobe Yukinori Sakao, MD, PhD,* Sakae Okumura, MD,* Mun Mingyon,
More informationPrevalence and Pattern of Lymph Node Metastasis in Malignant Pleural Mesothelioma
Prevalence and Pattern of Lymph Node Metastasis in Malignant Pleural Mesothelioma Abdel Rahman M. Abdel Rahman, MD, Rabab M. Gaafar, MD, Hoda A. Baki, MD, Hesham M. El Hosieny, MD, Fatma Aboulkasem, MD,
More informationTherapeutic Surgery for Nonepithelioid Malignant Pleural Mesothelioma: Is it Really Worthwhile?
Therapeutic Surgery for Nonepithelioid Malignant Pleural Mesothelioma: Is it Really Worthwhile? Bram Balduyck, MD, Delphine Trousse, MD, Apostolos Nakas, MD, Antonio E. Martin-Ucar, MD, John Edwards, MD,
More informationThe Journal of Thoracic and Cardiovascular Surgery
Accepted Manuscript Mesothelioma: Live to Fight Another Day Andrea S. Wolf, MD, Raja M. Flores, MD PII: S0022-5223(17)32747-2 DOI: 10.1016/j.jtcvs.2017.11.060 Reference: YMTC 12301 To appear in: The Journal
More informationThe role of surgical resection in the management of malignant
ORIGINAL ARTICLE Frequency of Use and Predictors of Cancer-Directed Surgery in the Management of Malignant Pleural Mesothelioma in a Community-Based (Surveillance, Epidemiology, and End Results [SEER])
More informationMalignant pleural mesothelioma (MPM) has a poor prognosis,
ORIGINAL ARTICLE Outcome for Patients with Malignant Pleural Mesothelioma Referred for Trimodality Therapy in Western Australia Arman Hasani, MBBS, FRACP,* John M. Alvarez, MBBS, FRACS, Jenny Ma Wyatt,
More informationInduction chemotherapy followed by surgical resection
Surgical Resection for Residual N 2 Disease After Induction Chemotherapy Jeffrey L. Port, MD, Robert J. Korst, MD, Paul C. Lee, MD, Matthew A. Levin, BS, David E. Becker, MA, Roger Keresztes, MD, and Nasser
More informationSuperior and Basal Segment Lung Cancers in the Lower Lobe Have Different Lymph Node Metastatic Pathways and Prognosis
ORIGINAL ARTICLES: Superior and Basal Segment Lung Cancers in the Lower Lobe Have Different Lymph Node Metastatic Pathways and Prognosis Shun-ichi Watanabe, MD, Kenji Suzuki, MD, and Hisao Asamura, MD
More informationPositron emission tomography predicts survival in malignant pleural mesothelioma
Flores et al General Thoracic Surgery Positron emission tomography predicts survival in malignant pleural mesothelioma Raja M. Flores, MD, a Timothy Akhurst, MD, b Mithat Gonen, PhD, c Maureen Zakowski,
More informationComplex Thoracoscopic Resections for Locally Advanced Lung Cancer
Complex Thoracoscopic Resections for Locally Advanced Lung Cancer Duke Thoracoscopic Lobectomy Workshop March 21, 2018 Thomas A. D Amico MD Gary Hock Professor of Surgery Section Chief, Thoracic Surgery,
More informationPneumonectomy After Induction Rx: Is it Safe?
Pneumonectomy After Induction Rx: Is it Safe? David J. Sugarbaker, M.D. Director, Chief, Division of Thoracic Surgery The Olga Keith Weiss Chair of Surgery of Medicine at, Pneumonectomy after induction
More informationExtrapleural Pneumonectomy: A Blessing or a Curse in the Management of Pleural Malignant Mesothelioma?
Original Research Extrapleural Pneumonectomy: A Blessing or a Curse in the Management of Pleural Malignant Mesothelioma? PLEURA January-December 2015: 1-7 ª The Author(s) 2015 DOI: 10.1177/2373997515595219
More informationT3 NSCLC: Chest Wall, Diaphragm, Mediastinum
for T3 NSCLC: Chest Wall, Diaphragm, Mediastinum AATS Postgraduate Course April 29, 2012 Thomas A. D Amico MD Professor of Surgery, Chief of Thoracic Surgery Duke University Health System Disclosure No
More informationTechnical pitfalls and solutions in extrapleural pneumonectomy
Safeguards and Pitfalls Technical pitfalls and solutions in extrapleural pneumonectomy Stephane Collaud, Marc de Perrot Toronto Mesothelioma Research Program, Toronto General Hospital and Princess Margaret
More informationVisceral pleural involvement (VPI) of lung cancer has
Visceral Pleural Involvement in Nonsmall Cell Lung Cancer: Prognostic Significance Toshihiro Osaki, MD, PhD, Akira Nagashima, MD, PhD, Takashi Yoshimatsu, MD, PhD, Sosuke Yamada, MD, and Kosei Yasumoto,
More informationThe incidence of malignant pleural mesothelioma
Operation and Photodynamic Therapy for Pleural Mesothelioma: 6-Year Follow-up Thomas L. Moskal, MD, Thomas J. Dougherty, PhD, John D. Urschel, MD, Joseph G. Antkowiak, MD, Anne-Marie Regal, MD, Deborah
More informationStandardizing surgical treatment in malignant pleural mesothelioma
Perspective Standardizing surgical treatment in malignant pleural mesothelioma David Rice University of Texas M.D. Anderson Cancer Center, Houston, TX, USA Corresponding to: David Rice. University of Texas
More informationPreoperative Chemotherapy Does Not Increase Complications After Nonsmall Cell Lung Cancer Resection
Preoperative Chemotherapy Does Not Increase Complications After Nonsmall Cell Lung Cancer Resection Emilie Perrot, MD, Benoit Guibert, MD, Pierre Mulsant, MD, Sonia Blandin, MD, Isabelle Arnaud, MD, Pascal
More informationCurrent Management of Postpneumonectomy Bronchopleural Fistula
Current Management of Postpneumonectomy Bronchopleural Fistula Shaf Keshavjee MD MSc FRCSC FACS Surgeon-in-Chief, University Health Network James Wallace McCutcheon Chair in Surgery Professor, Division
More informationThoracoplasty for the Management of Postpneumonectomy Empyema
ISPUB.COM The Internet Journal of Thoracic and Cardiovascular Surgery Volume 9 Number 2 Thoracoplasty for the Management of Postpneumonectomy Empyema S Mullangi, G Diaz-Fuentes, S Khaneja Citation S Mullangi,
More informationORIGINAL PAPER. Marginal pulmonary function is associated with poor short- and long-term outcomes in lung cancer surgery
Nagoya J. Med. Sci. 79. 37 ~ 42, 2017 doi:10.18999/nagjms.79.1.37 ORIGINAL PAPER Marginal pulmonary function is associated with poor short- and long-term outcomes in lung cancer surgery Naoki Ozeki, Koji
More informationPrognostic value of visceral pleura invasion in non-small cell lung cancer q
European Journal of Cardio-thoracic Surgery 23 (2003) 865 869 www.elsevier.com/locate/ejcts Prognostic value of visceral pleura invasion in non-small cell lung cancer q Jeong-Han Kang, Kil Dong Kim, Kyung
More informationThoracic Surgery; An Overview
Thoracic Surgery What we see Thoracic Surgery; An Overview James P. Locher, Jr, MD Methodist Cardiovascular and Thoracic Surgery Lung cancer Mets Fungus and TB Lung abcess and empyema Pleural based disease
More informationProper Treatment Selection May Improve Survival in Patients With Clinical Early-Stage Nonsmall Cell Lung Cancer
Proper Treatment Selection May Improve Survival in Patients With Clinical Early-Stage Nonsmall Cell Lung Cancer Özcan Birim, MD, A. Pieter Kappetein, MD, PhD, Tom Goorden, MD, Rob J. van Klaveren, MD,
More informationExtended pleurectomy decortication for malignant pleural mesothelioma in the elderly: the need for an inclusive yet selective approach
Interactive CardioVascular and Thoracic Surgery 25 (2017) 696 702 doi:10.1093/icvts/ivx221 Advance Access publication 21 July 2017 ORIGINAL ARTICLE Cite this article as: Sharkey AJ, Bilancia R, Tenconi
More informationMEDIASTINAL LYMPH NODE METASTASIS IN PATIENTS WITH CLINICAL STAGE I PERIPHERAL NON-SMALL-CELL LUNG CANCER
MEDIASTINAL LYMPH NODE METASTASIS IN PATIENTS WITH CLINICAL STAGE I PERIPHERAL NON-SMALL-CELL LUNG CANCER Tsuneyo Takizawa, MD a Masanori Terashima, MD a Teruaki Koike, MD a Hideki Akamatsu, MD a Yuzo
More informationGTS. The Journal of Thoracic and Cardiovascular Surgery c Volume 145, Number 4 955
Hyperthermic intraoperative pleural cisplatin chemotherapy extends interval to recurrence and survival among low-risk patients with malignant pleural mesothelioma undergoing surgical macroscopic complete
More informationMalignant pleural mesothelioma (MPM) affects nearly
ORIGINAL ARTICLE Patterns of Local and Nodal Failure in Malignant Pleural Mesothelioma After Extrapleural Pneumonectomy and Photon-Electron Radiotherapy Vishal Gupta, MD,* Lee M. Krug, MD, Benjamin Laser,
More informationThe Imaging Journey of Patients with Malignant Pleural Mesothelioma: Experience of a Tertiary Mesothelioma MDT
The Imaging Journey of Patients with Malignant Pleural Mesothelioma: Experience of a Tertiary Mesothelioma MDT V. Lam, J. Brozik, A. J. Sharkey, A. Bajaj, D. T. Barnes Glenfield Hospital, Leicester, United
More informationPDF hosted at the Radboud Repository of the Radboud University Nijmegen
PDF hosted at the Radboud Repository of the Radboud University Nijmegen The following full text is a publisher's version. For additional information about this publication click this link. http://hdl.handle.net/2066/23566
More informationPreoperative Workup for Pulmonary Resection. Kristen Bridges, M.D. Richmond University Medical Center January 21, 2016
Preoperative Workup for Pulmonary Resection Kristen Bridges, M.D. Richmond University Medical Center January 21, 2016 Patient Presentation 50 yo male with 70 pack year smoking history Large R hilar lung
More informationCorrelation of pretreatment surgical staging and PET SUV(max) with outcomes in NSCLC. Giancarlo Moscol, MD PGY-5 Hematology-Oncology UTSW
Correlation of pretreatment surgical staging and PET SUV(max) with outcomes in NSCLC Giancarlo Moscol, MD PGY-5 Hematology-Oncology UTSW BACKGROUND AJCC staging 1 gives valuable prognostic information,
More informationLymph node dissection for lung cancer is both an old
LOBE-SPECIFIC EXTENT OF SYSTEMATIC LYMPH NODE DISSECTION FOR NON SMALL CELL LUNG CARCINOMAS ACCORDING TO A RETROSPECTIVE STUDY OF METASTASIS AND PROGNOSIS Hisao Asamura, MD Haruhiko Nakayama, MD Haruhiko
More informationNorth of Scotland Cancer Network Clinical Management Guideline for Mesothelioma
THIS DOCUMENT IS North of Scotland Cancer Network Clinical Management Guideline for Mesothelioma [Based on WOSCAN SCLC CMG with further extensive consultation within NOSCAN] UNCONTROLLED WHEN PRINTED Document
More informationTreatment Strategy for Patients With Surgically Discovered N2 Stage IIIA Non-Small Cell Lung Cancer
Treatment Strategy for Patients With Surgically Discovered N2 Stage IIIA Non-Small Cell Lung Cancer Ryoichi Nakanishi, MD, Toshihiro Osaki, MD, Kozo Nakanishi, MD, Ichiro Yoshino, MD, Takashi Yoshimatsu,
More informationLung cancer pleural invasion was recognized as a poor prognostic
Visceral pleural invasion classification in non small cell lung cancer: A proposal on the basis of outcome assessment Kimihiro Shimizu, MD a Junji Yoshida, MD a Kanji Nagai, MD a Mitsuyo Nishimura, MD
More informationComparison of complete and minimal mediastinal lymph node dissection for non-small cell lung cancer: Results of a prospective randomized trial
Thoracic Cancer ISSN 1759-7706 ORIGINAL ARTICLE Comparison of complete and minimal mediastinal lymph node dissection for non-small cell lung cancer: Results of a prospective randomized trial Junhua Zhang*,
More informationVideo-Mediastinoscopy Thoracoscopy (VATS)
Surgical techniques Video-Mediastinoscopy Thoracoscopy (VATS) Gunda Leschber Department of Thoracic Surgery ELK Berlin Chest Hospital, Berlin, Germany Teaching Hospital of Charité Universitätsmedizin Berlin
More informationMalignant pleural mesothelioma (MPM) remains a major
Original Article Pleurectomy/Decortication is Superior to Extrapleural Pneumonectomy in the Multimodality Management of Patients with Malignant Pleural Mesothelioma Loïc Lang-Lazdunski, MD*, Andrea Bille,
More informationMEDIASTINAL STAGING surgical pro
MEDIASTINAL STAGING surgical pro Paul E. Van Schil, MD, PhD Department of Thoracic and Vascular Surgery University of Antwerp, Belgium Mediastinal staging Invasive techniques lymph node mapping cervical
More informationRoutine reinforcement of bronchial stump after lobectomy or pneumonectomy with pedicled pericardial flap (PPF)
Routine reinforcement of bronchial stump after lobectomy or pneumonectomy with pedicled pericardial flap (PPF) Abstract The results of 25 cases underwent a pedicled pericardial flap coverage for the bronchial
More informationThe Journal of Thoracic and Cardiovascular Surgery
Accepted Manuscript Can We Make Pneumonectomy Great Again? Kenneth A. Kesler, MD PII: S0022-5223(18)31793-8 DOI: 10.1016/j.jtcvs.2018.06.048 Reference: YMTC 13173 To appear in: The Journal of Thoracic
More informationMalignant Pleural Mesothelioma COMBINED TREATMENT
Malignant Pleural Mesothelioma COMBINED TREATMENT Federica Grosso incidence Italy
More informationValidation of the T descriptor in the new 8th TNM classification for non-small cell lung cancer
Original Article Validation of the T descriptor in the new 8th TNM classification for non-small cell lung cancer Hee Suk Jung 1, Jin Gu Lee 2, Chang Young Lee 2, Dae Joon Kim 2, Kyung Young Chung 2 1 Department
More informationMediastinal Staging. Samer Kanaan, M.D.
Mediastinal Staging Samer Kanaan, M.D. Overview Importance of accurate nodal staging Accuracy of radiographic staging Mediastinoscopy EUS EBUS Staging TNM Definitions T Stage Size of the Primary Tumor
More informationPrognostic Factors for Survival of Stage IB Upper Lobe Non-small Cell Lung Cancer Patients: A Retrospective Study in Shanghai, China
www.springerlink.com Chin J Cancer Res 23(4):265 270, 2011 265 Original Article Prognostic Factors for Survival of Stage IB Upper Lobe Non-small Cell Lung Cancer Patients: A Retrospective Study in Shanghai,
More informationMalignant pleural mesothelioma: key determinants in tailoring the right treatment for the right patient
Editorial Malignant pleural mesothelioma: key determinants in tailoring the right treatment for the right patient Ori Wald, David J. Sugarbaker Division of General Thoracic Surgery, Michael E. DeBakey
More informationLYMPH NODE METASTASIS IN SMALL PERIPHERAL ADENOCARCINOMA OF THE LUNG
LYMPH NODE METASTASIS IN SMALL PERIPHERAL ADENOCARCINOMA OF THE LUNG Tsuneyo Takizawa, MD a Masanori Terashima, MD a Teruaki Koike, MD a Takehiro Watanabe, MD a Yuzo Kurita, MD b Akira Yokoyama, MD b Keiichi
More informationThe tumor, node, metastasis (TNM) staging system of lung
ORIGINAL ARTICLE Peripheral Direct Adjacent Lobe Invasion Non-small Cell Lung Cancer Has a Similar Survival to That of Parietal Pleural Invasion T3 Disease Hao-Xian Yang, MD, PhD,* Xue Hou, MD, Peng Lin,
More informationNorth of Scotland Cancer Network Clinical Management Guideline for Non Small Cell Lung Cancer
THIS DOCUMENT IS North of Scotland Cancer Network Clinical Management Guideline for Non Small Cell Lung Cancer [Based on WOSCAN NSCLC CMG with further extensive consultation within NOSCAN] UNCONTROLLED
More informationBronchogenic Carcinoma
A 55-year-old construction worker has smoked 2 packs of ciggarettes daily for the past 25 years. He notes swelling in his upper extremity & face, along with dilated veins in this region. What is the most
More informationChemotherapy Induced Pathologic Complete Response in Malignant Pleural Mesothelioma. A Review and Case Report
STATE OF THE ART: CONCISE REVIEW Chemotherapy Induced Pathologic Complete Response in Malignant Pleural Mesothelioma A Review and Case Report Cecilia Bech, MD, and Jens Benn Sørensen, MD, DMSc, MPA Introduction:
More informationAccepted Manuscript. Surgery for mesothelioma: less is more, more or less. Steven Milman, MD, Thomas Ng, MD
Accepted Manuscript Surgery for mesothelioma: less is more, more or less Steven Milman, MD, Thomas Ng, MD PII: S0022-5223(17)32706-X DOI: 10.1016/j.jtcvs.2017.11.029 Reference: YMTC 12266 To appear in:
More informationPredictive risk factors for lymph node metastasis in patients with small size non-small cell lung cancer
Original Article Predictive risk factors for lymph node metastasis in patients with small size non-small cell lung cancer Feichao Bao, Ping Yuan, Xiaoshuai Yuan, Xiayi Lv, Zhitian Wang, Jian Hu Department
More informationMalignant pleural mesothelioma: Role of MDCT in early diagnosis and prediction of resectability for radical surgery
Malignant pleural mesothelioma: Role of MDCT in early diagnosis and prediction of resectability for radical surgery Poster No.: C-0890 Congress: ECR 2010 Type: Educational Exhibit Topic: Chest Authors:
More informationExperience has proven that pneumonectomy is a safe
Pneumonectomy After Chemoradiation Therapy for Non-Small Cell Lung Cancer: Does Side Really Matter? Anthony W. Kim, MD, L. Penfield Faber, MD, William H. Warren, MD, Sanjib Basu, PhD, Sean C. Wightman,
More informationA Proposed Strategy for Treatment of Superficial Carcinoma. in the Thoracic Esophagus Based on an Analysis. of Lymph Node Metastasis
Kitakanto Med J 2002 ; 52 : 189-193 189 A Proposed Strategy for Treatment of Superficial Carcinoma in the Thoracic Esophagus Based on an Analysis of Lymph Node Metastasis Susumu Kawate,' Susumu Ohwada,'
More informationAdrenal glands are a common metastatic site for non small cell lung cancer
Surgical treatment of solitary adrenal metastasis from non small cell lung cancer Olaf Mercier, MD, Elie Fadel, MD, PhD, Marc de Perrot, MD, Sacha Mussot, MD, Franco Stella, MD, Alain Chapelier, MD, PhD,
More informationMalignant pleural mesothelioma (MPM) is an aggressive
ORIGINAL ARTICLE Tomotherapy after Pleurectomy/Decortication or Biopsy for Malignant Pleural Mesothelioma Allows the Delivery of High Dose of Radiation in Patients with Intact Lung Emilio Minatel, MD,*
More informationTristate Lung Meeting 2014 Pro-Con Debate: Surgery has no role in the management of certain subsets of N2 disease
Tristate Lung Meeting 2014 Pro-Con Debate: Surgery has no role in the management of certain subsets of N2 disease Jennifer E. Tseng, MD UFHealth Cancer Center-Orlando Health Sep 12, 2014 Background Approximately
More informationPostoperative Mortality in Lung Cancer Patients
Review Postoperative Mortality in Lung Cancer Patients Kanji Nagai, MD, Junji Yoshida, MD, and Mitsuyo Nishimura, MD Surgery for lung cancer frequently results in serious life-threatening complications,
More informationExtent of visceral pleural invasion and the prognosis of surgically resected node-negative non-small cell lung cancer
Thoracic Cancer ISSN 1759-7706 ORIGINAL ARTICLE Extent of visceral pleural invasion and the prognosis of surgically resected node-negative non-small cell lung cancer Yangki Seok 1, Ji Yun Jeong 2 & Eungbae
More informationAfter primary tumor treatment, 30% of patients with malignant
ESTS METASTASECTOMY SUPPLEMENT Alberto Oliaro, MD, Pier L. Filosso, MD, Maria C. Bruna, MD, Claudio Mossetti, MD, and Enrico Ruffini, MD Abstract: After primary tumor treatment, 30% of patients with malignant
More informationThoracoscopic Lobectomy for Locally Advanced Lung Cancer. Masters of Minimally Invasive Thoracic Surgery Orlando September 19, 2014
for Locally Advanced Lung Cancer Masters of Minimally Invasive Thoracic Surgery Orlando September 19, 2014 Thomas A. D Amico MD Gary Hock Endowed Professor and Vice Chair of Surgery Chief Thoracic Surgery
More informationLung Cancer 83 (2014) Contents lists available at ScienceDirect. Lung Cancer. journal homepage:
Lung Cancer 83 (2014) 78 82 Contents lists available at ScienceDirect Lung Cancer journal homepage: www.elsevier.com/locate/lungcan Radical pleurectomy/decortication followed by high dose of radiation
More informationPRINCESS MARGARET CANCER CENTRE CLINICAL PRACTICE GUIDELINES
PRINCESS MARGARET CANCER CENTRE CLINICAL PRACTICE GUIDELINES LUNG SITE MESOTHELIOMA Lung Site Group Mesothelioma Authors: Dr. Meredith Giuliani, Dr. Andrea Bezjak 1. INTRODUCTION 3 2. PREVENTION 3 3. SCREENING
More informationAlthough the international TNM classification system
Prognostic Significance of Perioperative Serum Carcinoembryonic Antigen in Non-Small Cell Lung Cancer: Analysis of 1,000 Consecutive Resections for Clinical Stage I Disease Morihito Okada, MD, PhD, Wataru
More informationThe Itracacies of Staging Patients with Suspected Lung Cancer
The Itracacies of Staging Patients with Suspected Lung Cancer Gerard A. Silvestri, MD,MS, FCCP Professor of Medicine Medical University of South Carolina Charleston, SC silvestri@musc.edu Staging Lung
More informationPatient Selection for Surgery in RCC with Thrombus. E. Jason Abel, M.D.
Patient Selection for Surgery in RCC with Thrombus E. Jason Abel, M.D. RCC with venous invasion Venous invasion occurs in ~10% of RCC Surgery more complex Increased risk for morbidity Thrombus may be confined
More informationTransfusion & Mortality. Philippe Van der Linden MD, PhD
Transfusion & Mortality Philippe Van der Linden MD, PhD Conflict of Interest Disclosure In the past 5 years, I have received honoraria or travel support for consulting or lecturing from the following companies:
More informationESTS SCHOOL OF THORACIC SURGERY Antalya Revisited in Istanbul March 2016 Istanbul, Turkey
ESTS SCHOOL OF THORACIC SURGERY Antalya Revisited in Istanbul 16-20 March 2016 Istanbul, Turkey Format 1. Lectures, Video and Case Presentations 15 min. 2. Learn from Peers Sessions. 3. More integrated
More informationLung cancer involving neighboring structures is classified
GENERAL THORACIC Subcategorization of Resectable Non-Small Cell Lung Cancer Involving Neighboring Structures Noriaki Sakakura, MD, Shoichi Mori, MD, Futoshi Ishiguro, MD, Takayuki Fukui, MD, Shunzo Hatooka,
More informationTreatment of malignant pleural mesothelioma (MPM)
Original Article A New Prognostic Score Supporting Treatment Allocation for Multimodality Therapy for Malignant Pleural Mesothelioma A Review of 12 Years Experience Isabelle Opitz, MD,* Martina Friess,
More informationNode-Negative Non-small Cell Lung Cancer
ORIGINAL ARTICLE Node-Negative Non-small Cell Lung Cancer Pathological Staging and Survival in 1765 Consecutive Cases Benjamin M. Robinson, BSc, MBBS, Catherine Kennedy, RMRA, Jocelyn McLean, RN, MN, and
More informationIndex. Note: Page numbers of article titles are in boldface type.
Note: Page numbers of article titles are in boldface type. A Ablative therapy, nonsurgical, for pulmonary metastases of soft tissue sarcoma, 279 280 Adipocytic tumors, atypical lipomatous tumor vs. well-differentiated
More informationLONG-TERM SURGICAL OUTCOMES OF 1018 PATIENTS WITH EARLY STAGE NSCLC IN ACOSOG Z0030 (ALLIANCE) TRIAL
LONG-TERM SURGICAL OUTCOMES OF 1018 PATIENTS WITH EARLY STAGE NSCLC IN ACOSOG Z0030 (ALLIANCE) TRIAL Stacey Su, MD; Walter J. Scott, MD; Mark S. Allen, MD; Gail E. Darling, MD; Paul A. Decker, MS; Robert
More informationRevisit of Primary Malignant Neoplasms of the Trachea: Clinical Characteristics and Survival Analysis
Jpn J Clin Oncol 1997;27(5)305 309 Revisit of Primary Malignant Neoplasms of the Trachea: Clinical Characteristics and Survival Analysis -, -, - - 1 Chest Department and 2 Section of Thoracic Surgery,
More informationImpact of blood transfusions on outcome after pneumonectomy for thoracic malignancies
Eur Respir J 2007; 29: 565 570 DOI: 10.1183/09031936.00059506 CopyrightßERS Journals Ltd 2007 Impact of blood transfusions on outcome after pneumonectomy for thoracic malignancies P. Thomas*,#, P. Michelet*,",
More informationPleurectomy-decortication (P/D) was first popularized in
Technique of Pleurectomy and Decortication Andrew J. Kaufman, MD, and Raja M. Flores, MD Pleurectomy-decortication (P/D) was first popularized in the mid 1950s as a surgical method for treating entrapped
More informationSlide 1. Slide 2. Slide 3. Investigation and management of lung cancer Robert Rintoul. Epidemiology. Risk factors/aetiology
Slide 1 Investigation and management of lung cancer Robert Rintoul Department of Thoracic Oncology Papworth Hospital Slide 2 Epidemiology Second most common cancer in the UK (after breast). 38 000 new
More informationAccording to the current International Union
Treatment of Stage II Non-small Cell Lung Cancer* Walter J. Scott, MD, FCCP; John Howington, MD, FCCP; and Benjamin Movsas, MD Based on clinical assessment alone, patients with stage II non-small cell
More informationPrognostic factors of postrecurrence survival in completely resected stage I non-small cell lung cancer with distant metastasis
< A supplementary figure and table are published online only at http://thx.bmj.com/content/ vol65/issue3. 1 Institute of Clinical Medicine, National Yang-Ming University, 2 Department of Surgery, Cathay
More informationLymph node metastasis is one of the most important prognostic
ORIGINAL ARTICLE Comparison of Survival and Recurrence Pattern Between Two-Field and Three-Field Lymph Node Dissections for Upper Thoracic Esophageal Squamous Cell Carcinoma Young Mog Shim, MD, Hong Kwan
More informationRole of adjuvant chemotherapy after pneumonectomy for non-small cell lung cancer
ONCOLOGY LETTERS 4: 1349-1353, 2012 Role of adjuvant chemotherapy after pneumonectomy for non-small cell lung cancer MENG WANG 1,2, JING ZHAO 3, YAN-JUN SU 1,2, XIAO-LIANG ZHAO 1,2 and CHANG-LI WANG 1,2
More informationThe accurate assessment of lymph node involvement is
ORIGINAL ARTICLE Which is the Better Prognostic Factor for Resected Non-small Cell Lung Cancer The Number of Metastatic Lymph Nodes or the Currently Used Nodal Stage Classification? Shenhai Wei, MD, PhD,*
More informationSTS General Thoracic Surgery Database (GTSD) Update
STS General Thoracic Surgery Database (GTSD) Update Benjamin D. Kozower, MD, MPH Professor of Surgery Chair, STS GTSD Co-Director, Surgical Outcomes Research Center Washington University St. Louis, MO
More informationSystemic Management of Malignant Pleural Mesothelioma
ESO-ESMO EASTERN EUROPE AND BALKAN REGION MASTERCLASS IN MEDICAL ONCOLOGY 15.June-19.June 2018 Belgrade, Serbia Systemic Management of Malignant Pleural Mesothelioma Dragana Jovanovic University Hospital
More informationSatellite Pulmonary Nodule in the Same Lobe (T4N0) Should Not Be Staged as IIIB Non Small Cell Lung Cancer
Satellite Pulmonary Nodule in the Same Lobe (T4N0) Should Not Be Staged as IIIB Non Small Cell Lung Cancer Ayesha S. Bryant, MSPH, MD, Sara J. Pereira, MD, Daniel L. Miller, MD, and Robert James Cerfolio,
More informationIndeterminate Pulmonary Nodules in Patients with Colorectal Cancer
Indeterminate Pulmonary Nodules in Patients with Colorectal Cancer Jai Sule 1, Kah Wai Cheong 2, Stella Bee 2, Bettina Lieske 2,3 1 Dept of Cardiothoracic and Vascular Surgery, University Surgical Cluster,
More informationMediastinal Lymph Node Dissection Improves Survival in Patients With Stages II and IIIa Non- Small Cell Lung Cancer
J. MAXWELL CHAMBERLAIN MEMORIAL PAPER Mediastinal Lymph Node Dissection Improves Survival in Patients With Stages II and IIIa Non- Small Cell Lung Cancer Steven M. Keller, MD, Sudeshna Adak, PhD, Henry
More informationTitle: What has changed in the surgical treatment strategies of non-small cell lung cancer in
1 Manuscript type: Original Article DOI: Title: What has changed in the surgical treatment strategies of non-small cell lung cancer in twenty years? A single centre experience Short title: Changes in the
More informationHistologic Assessment and Prognostic Factors of Malignant Pleural Mesothelioma Treated With Extrapleural Pneumonectomy
Anatomic Pathology / Malignant Pleural Mesothelioma Histologic Assessment and Prognostic Factors of Malignant Pleural Mesothelioma Treated With Extrapleural Pneumonectomy Andrea V. Arrossi, MD, 1 E. Lin,
More informationCheng-Yang Song, Takehiro Sakai, Daisuke Kimura, Takao Tsushima, Ikuo Fukuda
Original Article Comparison of perioperative and oncological outcomes between video-assisted segmentectomy and lobectomy for patients with clinical stage IA non-small cell lung cancer: a propensity score
More informationIndex. Note: Page numbers of article titles are in boldface type
Index Note: Page numbers of article titles are in boldface type A Acute coronary syndrome, perioperative oxygen in, 599 600 Acute lung injury (ALI). See Lung injury and Acute respiratory distress syndrome.
More informationPulmonary resection for lung cancer with malignant pleural disease first detected at thoracotomy
European Journal of Cardio-Thoracic Surgery 41 (2012) 25 30 doi:10.1016/j.ejcts.2011.04.010 ORIGINAL ARTICLE Pulmonary resection for lung cancer with malignant pleural disease first detected at thoracotomy
More informationNon small-cell lung cancers (NSCLCs) located along
Original Article Long-Term Outcome after En Bloc Resection of Non Small-Cell Lung Cancer Invading the Pulmonary Sulcus and Spine Stéphane Collaud, MD, MSc,* Thomas K. Waddell, MD, PhD,* Kazuhiro Yasufuku,
More informationNumber of Metastatic Lymph Nodes in Resected Non Small Cell Lung Cancer Predicts Patient Survival
Number of Metastatic Lymph Nodes in Resected Non Small Cell Lung Cancer Predicts Patient Survival Jin Gu Lee, MD, Chang Young Lee, MD, In Kyu Park, MD, Dae Joon Kim, MD, Seong Yong Park, MD, Kil Dong Kim,
More informationNon-Small Cell Lung Cancer: Disease Spectrum and Management in a Tertiary Care Hospital
Non-Small Cell Lung Cancer: Disease Spectrum and Management in a Tertiary Care Hospital Muhammad Rizwan Khan,Sulaiman B. Hasan,Shahid A. Sami ( Department of Surgery, The Aga Khan University Hospital,
More information